Doximity Inc. shares plunged in after-hours trading on the New York Stock Exchange after the company reported mixed fourth-quarter results [1].
The drop reflects investor concern over the company's future growth trajectory and its ability to maintain margins amid shifting pharmaceutical spending patterns.
For the fourth quarter of fiscal 2026, Doximity reported adjusted earnings per share (EPS) of $0.26 [2]. This figure represents a 31.6% decline year-over-year [2]. The result was 7.1% below the Zacks Consensus Estimate [2]. Additionally, the company reported a GAAP EPS of $0.10 for the quarter [2].
While the company saw some revenue beats, the market reaction was driven largely by weak forward guidance. Management said delayed pharmaceutical industry budgets were a primary factor contributing to the lower revenue outlook for the next fiscal year [3].
These financial headwinds contrast with some internal operational metrics. Reports from the company's earnings call suggested a balance between robust profitability and cash generation, alongside significant investments in artificial intelligence [4]. However, the immediate market response focused on the missed earnings and the cautious outlook provided by leadership [1].
The company, which operates as a professional network for clinicians, now faces pressure to prove it can navigate the volatility of pharmaceutical budget cycles while scaling its AI initiatives [4].
“Doximity reported adjusted earnings per share (EPS) of $0.26, down 31.6% year-over-year.”
The sharp decline in Doximity's stock highlights the sensitivity of telehealth and healthcare networking platforms to the budgeting cycles of the pharmaceutical industry. While the company is investing heavily in AI to drive long-term value, the immediate reliance on pharma-driven revenue makes it vulnerable to short-term corporate spending delays, creating a gap between operational health and market valuation.
